Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 11/20 | 0.52 |
| ▸ | CDC25B | P30305 | 9/20 | 0.52 |
| ▸ | PTPN2 | P17706 | 7/20 | 0.52 |
| ▸ | PTPN11 | Q06124 | 6/20 | 0.52 |
| ▸ | PTPN6 | P29350 | 5/20 | 0.52 |
| ▸ | TACR2 | P21452 | 3/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | CDC25A | P30304 | 1/20 | 0.45 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.44 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.44 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.44 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.44 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5948268 | 1.00 | NT5E (0.53) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL5948514 | 0.93 | PTPN1 (0.51) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL10951228 | 0.84 | PTPN1 (0.48) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL21657197 | 0.83 | HTR1A (0.50) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL10945737 | 0.82 | PTPN1 (0.50) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL3898367 | 0.82 | NT5E (0.54) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL15968116 | 0.82 | NT5E (0.54) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL3898371 | 0.82 | NT5E (0.54) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL17766609 | 0.82 | NT5E (0.54) | NT5EPTPN1CDC25BPTPN2PTPN11 | |
| SCHEMBL10400344 | 0.81 | HTR1A (0.51) | NT5EPTPN1CDC25BPTPN2PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060205677-A1 | Platinum-containing compounds exhibiting cytostatic activity, synthesis and methods of use | XENOPORT, INC. | 2006-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205677-A1 | Platinum-containing compounds exhibiting cytostatic activity, synthesis and methods of use | TYMP, TOP1, TOP2A | NT5E 1926/4885PTPN1 3309/4885CDC25B 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.